ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1902

Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials

Yusuf Yazici1, Christopher Swearingen2, Heli Ghandehari3, ismail simsek4, Sarah Kennedy5, Jeyanesh Tambiah6 and Timothy McAlindon7, 1New York University School of Medicine, La Jolla, CA, 2Samumed LLC, San Diego, CA, 3Biosplice Therapeutics, Inc., San Diego, CA, 4Alpine Immunesciences, San Diego, CA, 5Biosplice Therapeutics, Inc, San Diego, CA, 6Biosplice Ther Inc., San Diego, CA, 7Tufts Medical Center, Arlington, MA

Meeting: ACR Convergence 2022

Keywords: clinical trial, Osteoarthritis, Outcome measures, radiography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Osteoarthritis (OA) is a leading cause of disability globally, and its disease burden is expected to increase as risk factors such as aging and obesity also rise (Wallace, IJ et al. PNAS 2017). Unmet needs remain for safe and efficacious treatments for both symptoms and structural modification. Disease heterogeneity and the difficulties assessing pain and joint structure in clinical trials are challenges to developing effective treatments options. This post hoc analysis of lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, examined the structural heterogeneity of participants enrolled in Phase 2 and 3 LOR trials and then the associated treatment responses within KL grade subgroups. The purpose of this analysis was to identify potential relationships between OA pain and knee joint structure which may aid future clinical trial design.

Methods: Data was analyzed from two Phase 2 (OA-02, NCT02536833; OA-04, NCT03122860), and two Phase 3 trials (OA-10, NCT04385303; OA-11, NCT03928184). In all trials, participants had ACR-defined (clinical and radiographic) knee OA, Kellgren-Lawrence (KL) grades 2-3. For OA-04, OA-10 and OA-11, additional criteria included Pain Numeric Rating Scale (NRS) [0-10] ≥4 and ≤8 in the target knee and < 4 in the contralateral knee. Baseline JSW for each study was compared using a cumulative frequency distribution plots by KL grade; percentages of subjects with JSW < 3mm for each study was also summarized to provide a surrogate for loss of ~50% healthy JSW (Deep et al. JBJS 2003). For the trials which captured Pain NRS, treatment responses were assessed according to KL grade and by trial. For all treatment-related outcomes, change from baseline was estimated using baseline-adjusted ANCOVA at each timepoint.

Results: In the Phase 2 trials, 16% (OA-02) and 21% (OA-04) and in the Phase 3 trials, 30% (OA-10) and 49% (OA-11) of KL 2 participants had baseline mJSW < 3 mm. For KL 3 participants, OA-02 had 55% and OA-04 53%, while OA-10 had 81% and OA-11 88% mJSW < 3mm (figure 1). Beneficial treatment effect of LOR vs. PBO was seen in KL 2 for OA-04 and OA-10, but not OA-11, with similar magnitude of response seen for 0.07 mg and 0.23 mg doses (figure 2). Beneficial treatment effect of LOR was seen only in OA-04 for KL 3, with similar magnitude of change for 0.07 mg and 0.23 mg LOR through week 12, and greater improvement observed for the 0.23 mg dose for weeks 12-24 (figure 3).

Conclusion: In this post hoc analysis, there was substantial heterogeneity in baseline mJSWs across LOR clinical trials within the KL 2-3 grade inclusion criteria. Participants with less structurally advanced knee OA showed greater pain treatment responses to 0.07 mg LOR compared to those with more advanced disease. These data support the hypothesis that the amount of OA structural damage is associated with the pain of knee OA and that earlier intervention may improve outcomes.

Supporting image 1

Figure 1. Cumulative frequency of baseline mJSW by KL grade across LOR trials

Supporting image 2

Figure 2. Treatment effect of LOR vs PBO by KL grade 2 across LOR trials

Supporting image 3

Figure 3. Treatment effect of LOR vs PBO by KL grade 3 across LOR trials


Disclosures: Y. Yazici, Amgen, Biosplice; C. Swearingen, Biosplice Therapeutics, Inc; H. Ghandehari, Biosplice Therapeutics, Inc.; i. simsek, Biosplice Inc.; S. Kennedy, Biosplice Therapeutics, Inc; J. Tambiah, Biosplice Therapeutics Inc; T. McAlindon, Biosplice Therapeutics, Inc, Remedium-Bio, Organogenesis, Pfizer, Kolon Tissue Gene, Seikugaku.

To cite this abstract in AMA style:

Yazici Y, Swearingen C, Ghandehari H, simsek i, Kennedy S, Tambiah J, McAlindon T. Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/structural-severity-in-knee-osteoarthritis-impacts-treatment-response-a-post-hoc-pooled-analysis-of-lorecivivint-clinical-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/structural-severity-in-knee-osteoarthritis-impacts-treatment-response-a-post-hoc-pooled-analysis-of-lorecivivint-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology